Zacks Investment Research upgraded shares of Coherus Biosciences (NASDAQ:CHRS) from a hold rating to a buy rating in a report published on Wednesday. They currently have $11.00 target price on the biotechnology company’s stock.

According to Zacks, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. “

Several other research firms have also weighed in on CHRS. ValuEngine lowered shares of Coherus Biosciences from a sell rating to a strong sell rating in a report on Friday, November 10th. BidaskClub upgraded shares of Coherus Biosciences from a sell rating to a hold rating in a report on Thursday, December 21st. Credit Suisse Group reiterated an outperform rating and issued a $17.00 target price (down from $24.00) on shares of Coherus Biosciences in a report on Wednesday, September 27th. Maxim Group reiterated a buy rating and issued a $20.00 target price (down from $40.00) on shares of Coherus Biosciences in a report on Friday, September 8th. Finally, Cowen reiterated an outperform rating and issued a $45.00 target price on shares of Coherus Biosciences in a report on Friday, September 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $29.67.

Coherus Biosciences (NASDAQ:CHRS) opened at $12.35 on Wednesday. The firm has a market cap of $739.58, a PE ratio of -2.28 and a beta of 3.89. Coherus Biosciences has a 52-week low of $8.05 and a 52-week high of $28.60. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.46 and a current ratio of 5.46.

Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. analysts anticipate that Coherus Biosciences will post -4.39 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN lifted its holdings in shares of Coherus Biosciences by 0.9% in the 2nd quarter. Wells Fargo & Company MN now owns 29,116 shares of the biotechnology company’s stock worth $418,000 after acquiring an additional 253 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Coherus Biosciences by 12.6% in the 2nd quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 1,046 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Coherus Biosciences by 2.3% in the 2nd quarter. California State Teachers Retirement System now owns 67,940 shares of the biotechnology company’s stock worth $975,000 after acquiring an additional 1,500 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Coherus Biosciences by 32.7% in the 2nd quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 1,785 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of Coherus Biosciences by 1.4% in the 2nd quarter. Principal Financial Group Inc. now owns 140,390 shares of the biotechnology company’s stock worth $2,015,000 after acquiring an additional 1,950 shares during the last quarter. Hedge funds and other institutional investors own 81.00% of the company’s stock.

WARNING: “Coherus Biosciences (CHRS) Upgraded at Zacks Investment Research” was originally published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/01/06/coherus-biosciences-chrs-upgraded-at-zacks-investment-research.html.

About Coherus Biosciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Get a free copy of the Zacks research report on Coherus Biosciences (CHRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.